Alliancebernstein L.P. Has $14.64 Million Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ

Alliancebernstein L.P. boosted its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 33.5% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 117,949 shares of the specialty pharmaceutical company’s stock after purchasing an additional 29,578 shares during the period. Alliancebernstein L.P.’s holdings in Jazz Pharmaceuticals were worth $14,643,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Captrust Financial Advisors lifted its position in shares of Jazz Pharmaceuticals by 7.5% in the fourth quarter. Captrust Financial Advisors now owns 5,337 shares of the specialty pharmaceutical company’s stock valued at $657,000 after buying an additional 372 shares during the last quarter. Cetera Investment Advisers acquired a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $1,243,000. EP Wealth Advisors LLC acquired a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $217,000. Deutsche Bank AG lifted its position in shares of Jazz Pharmaceuticals by 4.0% in the fourth quarter. Deutsche Bank AG now owns 16,012 shares of the specialty pharmaceutical company’s stock valued at $1,972,000 after buying an additional 609 shares during the last quarter. Finally, Focus Partners Wealth acquired a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $551,000. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $128.46 on Friday. The stock has a market cap of $7.79 billion, a PE ratio of -19.09, a PEG ratio of 7.87 and a beta of 0.24. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The firm’s fifty day moving average price is $118.26 and its two-hundred day moving average price is $116.82.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The firm had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter in the prior year, the firm earned $5.30 EPS. The company’s revenue was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, equities analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on JAZZ shares. Truist Financial boosted their price target on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the company a “buy” rating in a research note on Thursday, August 28th. Needham & Company LLC restated a “buy” rating and issued a $202.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Zacks Research upgraded Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. Deutsche Bank Aktiengesellschaft began coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They issued a “buy” rating and a $152.00 price target for the company. Finally, The Goldman Sachs Group lifted their price target on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a research report on Friday, August 29th. Fourteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $178.67.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total transaction of $771,720.00. Following the transaction, the director directly owned 429,973 shares of the company’s stock, valued at approximately $55,303,127.26. This represents a 1.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.30% of the stock is currently owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.